Global /United Kingdom /Healthcare /Drug Manufacturers - General /GSK
chevron_leftBack

GSK plc

GSK
LSE: GSK Delayed
1,379GBX 1.3%
18.30 USD
As of 24 April 2025, GSK plc has a market cap of $73.22B USD, ranking #246 globally and #13 in the United Kingdom. It ranks #31 in the Healthcare sector, and #15 in the Drug Manufacturers - General industry.
Global Rank
246
Country Rank
13
Sector Rank
31
Industry Rank
15
Key Stats
Market Cap
$73.22BUSD
55.19B GBP
Enterprise Value
$89.24BUSD
67.26B GBP
Revenue (TTM)
$41.63BUSD
31.38B GBP
EBITDA (TTM)
$11.03BUSD
8.31B GBP
Net Income (TTM)
$3.42BUSD
2.58B GBP
EBITDA Margin
26%
Profit Margin
8.2%
PE Ratio
21.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Emma Walmsley open_in_new
Employees
68,629
Founded
1715
Website
gsk.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.3% 2.5% -8.6% 1.7% -5.1% -16%
Upcoming Earnings
Earnings Date
Mon, Apr 28

Markets

Exchange Ticker Price
London Stock Exchange
MIC: XLON
PRIMARY
GSK
GSK PLC
ISIN: GB00BN7SWP63
Shares Out.:
4.052B1 Shares Float: 3.712B2
TV:
SA:
YF:
GF:
BA:
GSK
MS:
1.38K GBX
OTC Markets
MIC: OTCM
GLAXF
GSK PLC
ISIN: GB00BN7SWP63
TV:
SA:
YF:
GF:
BA:
MS:
18.79 USD
Deutsche Börse Xetra
MIC: XETR
GS71
GSK PLC
ISIN: GB00BN7SWP63
TV:
SA:
YF:
GF:
BA:
MS:
15.73 EUR
Frankfurt Stock Exchange
MIC: XFRA
GS71
GSK PLC
ISIN: GB00BN7SWP63
TV:
SA:
YF:
GF:
BA:
MS:
15.71 EUR
NYSE
MIC: XNYS
GSK
GSK PLC ADR
ISIN: US37733W2044
Shares Out.:
2.027B1 Shares Float: 2.027B2
TV:
SA:
YF:
GSK
GF:
NQ:
GSK
BA:
GSK
MS:
37.03 USD
Mexican Bolsa
MIC: XMEX
GSK1 (GSK1/N)
ISIN: GB00BN7SWP63
TV:
SA:
YF:
GF:
BA:
MS:
356.95 MXN
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop vaccines for influenza and COVID-19, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

Similar Companies

Industry: Drug Manufacturers - General (United Kingdom)
Name
Market Cap diff.
AstraZeneca PLC
AZN
$213.18B
160.68B GBP
191%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.65B
917%
Johnson & Johnson
JNJ
$374.1B
411%
AbbVie Inc.
ABBV
$313.02B
328%
Novo Nordisk A/S
NOVO-B
$262.78B
1.73T DKK
259%
Roche Holding AG
RO
$246.36B
204.44B CHF
236%